The ICNC 2016 organisation offers a wide range of sponsoring and exhibiting opportunities.
In order to receive more information and the sponsoring prospectus, please contact us at icnc2016@mci-group.com
PLATINUM
At Shire, we enable people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of novel orally administered drugs that target RNA mechanisms affecting protein production. It is PTC’s mission to bring new therapies to patients affected by rare and neglected diseases such as cystic fibrosis and Duchenne muscular dystrophy. For more information please visit www.ptcbio.com.
GOLD
Novartis Oncology is a global leader in transforming outcomes for people living with cancer and other diseases. We offer a wide range of innovative therapies to help meet patient needs and our oncology pipeline is one of the strongest and most productive in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information about how we are transforming the treatment of cancer and other diseases, visit www.novartisoncology.com
SILVER
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
BRONZE
BIOCODEX is a French independent pharmaceutical company relying on a global network of scientists and partners. This allowing to acquire, over the years, expertise in specific therapeutic areas, such as in orphan disease in children epilepsy, and now enables patients in over 100 countries to have access to its innovative medication. Powered by an industrial vision and innovation, BIOCODEX is committed to provide the best care to patients, emphasizing work on the long term in a constant dialogue with healthcare professionals.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
We would like to invite you to join the welcome reception at the RAI Amsterdam. Visit the RAI and mingle with you conference colleagues and exhibitor in an informal atmosphere, enjoying drinks and small bites.
Venue
RAI Amsterdam Europaplein 22 1078 GZ Amsterdam
Schedule
Sunday 1 May 2016
Opening Ceremony: 17.00-17.30
Welcome Reception: 17.30-19.30
Registration
This event is included in the registration fee.
CONGRESS OUTING
Venue
Scheepvaartmuseum / The National Maritime Museum Kattenburgerplein 1 1018 KK Amsterdam
Schedule
Wednesday 4 May 2016
Gala dinner
19.00-23.00
Transfer
Boat services are arranged from the conference venue to the Scheepvaartmuseum starting at 18.00 to 19.00. After 19.00 transportation should be arranged by yourself.
Pendel busses will leave from the Scheepvaartmuseum back to RAI from 22.00-23.30
Registration
This event is paid and registration is mandatory
The National Maritime Museum is housed in ‘s Lands Zeemagazijn (the Arsenal). This historic building dates from 1656 and was designed by Daniel Stalpaert as a storehouse for the Admiralty of Amsterdam.
The Arsenal was built in the Golden Age, when Amsterdam was the largest port and market place in the world. Goods from all over the world could be bought right here. Today, over 350 years later, the Arsenal remains an imposing and impressive building with a great deal of character. It exudes history, making it the perfect location for The National Maritime Museum, which has been housed here since 1973.
These sponsored lunch symposia are not a part of the CME accreditation
Monday May 2nd
12.15 – 13.45
Sponsored lunch symposium 3 – Tuberous Sclerosis Complex: new insights into seizures and cognition Room: Forum Novartis . Chair: Marie-Claire de Wit, the Netherlands
Neurological and neuropsychiatric manifestations of tuberous sclerosis complex Petrus de Vries, South Africa
Current treatments and emerging therapies for TSC-related seizures Paolo Curatolo, Italy
Potential of early intervention on improving neurological outcomes Anna Jansen, Belgium
Sponsored lunch symposium 4 – Emerging Findings for CLN2 Disease Early Diagnosis and Management – At the Intersection of Epilepsy and Genetics Room: Emerald Room BioMarin Pharmaceutical
CLN2 Disease and the Need for Early Diagnosis Ruth Williams, United Kingdom
Insights into Natural History and Strategies to Optimise Patient Outcomes Angela Schulz, Germany
Low Frequency IPS EEG – A Clue for Early Diagnosis Nicola Specchio, Italy
Tuesday May 3rd
12.15 – 13.45
Sponsored lunch symposium 3 – Identification of undiagnosed neurological disorders in paediatric patients: the hunt for Niemann-Pick disease Type C Room: Emerald Room Actelion Pharmaceuticals Ltd . Chair: Marc Patterson, U.S.A.
A needle in a haystack: differential diagnosis of NP-C in the paediatric population Charles Lourenço, Brazil
From NP-C suspicion to clinical practice Julian Raiman, United Kingdom
Latest advances in NP-C diagnosis: building on biomarkers Peter Clayton, United Kingdom
After diagnosis: treatment and monitoring of the disease Marc Patterson, U.S.A.
Sponsored lunch symposium 4 – Prolonged Seizures: Optimal Management of a Medical Emergency Room: E104-E107 Shire
Introduction, Definitions and Epidemiology of Prolonged Seizures Emilio Perucca, Italy
Prolonged Seizures: Mechanisms of Action of Rescue Medications Steve White, U.S.A.
Pharmacological Treatment of Prolonged Seizures: Treating Epileptic Seizures by the Clock Helen Cross, United Kingdom
Burden of Uncontrolled Prolonged Seizures and Status Epilepticus Alexis Arzimanoglou, France
Wednesday May 4th
12.15 – 13.45
Sponsored lunch symposium 4 – Early diagnosis and treatment: the cornerstone of effective management of Duchenne muscular dystrophy Room: Emerald Room PTC Therapeutics . Chair: Eugenio Mercuri, Italy
A typical journey in Duchenne muscular dystrophy: from diagnosis to referral and treatment Rosaline Quinlivan, United Kingdom
Why genetic testing is crucial for the accurate diagnosis of a patient with Duchenne muscular dystrophy Sylvie Tuffery-Giraud, France
What do the latest data tell us about the use of ataluren in the management of patients with nonsense mutation Duchenne muscular dystrophy? Eugenio Mercuri, Italy
Thursday May 5th
12.15 – 13.45
Sponsored lunch symposium 4 – Spotlight on SMA: latest perspectives and future landscapes . Room: Forum Biogen . Chair: Ludo van der Pol, the Netherlands
The continuum of disease symptoms and diagnosis of SMA Ludo van der Pol, the Netherlands
Multidisciplinary management of patients with SMA Eugenio Mercuri and Elena Mazzone, Italy
The evolving SMA treatment landscape: what does the future hold? Susan Iannaccone, U.S.A.
